Or you can make a one-dish meal that fits this model
PC1/3 antibody (ab220363) was obtained from Abcam (Cambridge, United Kingdom)
Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 diabetes mellitus: A meta-analysis
Answer: Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications that includes semaglutide (Wegovy, Ozempic, Rybelsus), tirzepatide (Zepbound, Mounjaro), liraglutide (Victoza, Saxenda), and orforglipron (Foundayo), have become increasingly popular for obesity treatment (Mehrtash, JAMA Intern Med 2025)
While it does activate GLP-1 receptors like semaglutide, it has five times stronger affinity for GIP receptors, creating a metabolic signal your body doesn't get from GLP-1 medications alone
It is the first dual incretin receptor agonist, activating both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors